


Data Sheet

Product Name:	Gly-β-MCA
Cat. No.:	CS-0037067
CAS No.:	66225-78-3
Molecular Formula:	C ₂₆ H ₄₃ NO ₆
Molecular Weight:	465.62
Target:	Autophagy; FXR
Pathway:	Autophagy; Metabolic Enzyme/Protease
Solubility:	DMSO : 125 mg/mL (268.46 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

Gly-β-MCA, a bile acid, is a potent, stable, intestine-selective and oral bioactive farnesoid X receptor (**FXR**) inhibitor that may be a candidate for the treatment of metabolic disorders^[1]. **IC₅₀ & Target:** FXR^[1]. **In Vitro:** Gly-β-MCA, a bile acid, is a potent, stable and intestine-selective and farnesoid X receptor (FXR) inhibitor^[1].

Gly-β-MCA (Gly-MCA,) is resistant to hydrolysis by BSH^[1]. **In Vivo:** Gly-β-MCA (Gly-MCA, p.o. 10 and 50 mg/kg) prevents and treats diet-induced and genetic obesity, along with insulin resistance and hepatic steatosis without systemic, hepatic or intestinal toxicities in mice^[1].

Gly-MCA does not increase faecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation^[1].

References:

[1]. Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6:10166.

CAIndexNames:

Glycine, N-[(3α,5β,6β,7β)-3,6,7-trihydroxy-24-oxocholan-24-yl]-

SMILES:

C[C@@H]1([C@@]1([H])CC[C@@]2([H])[C@@]3([H])[C@]([C@]4(CC[C@@H](O)C[C@H]4[C@H](O)[C@@H]3O)C)([H])CC[C@]12C)CCC(NCC(O)=O)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA